STOCK TITAN

Im Cannabis (IMCC) Stock News

IMCC Nasdaq

Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.

IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.

Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.

Rhea-AI Summary

IM Cannabis Corp (IMCC) has closed a non-brokered private placement of secured convertible debentures, raising $2,091,977. The debentures, maturing on May 26, 2025, may be converted to common shares at $0.85 per share and will not incur interest unless there is a default. This move aims to reduce financial costs and support accelerated growth in Germany following its recent legalization of cannabis. CEO Oren Shuster, a related party, subscribed for $237,214 in debentures. IMC has also reduced its 2023 G&A costs by 49% compared to 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary

IM Cannabis Corp. reported its financial results for Q1 2024, showing a 13% revenue increase compared to Q4 2023. Gross profit increased by 125% but dropped by 39% compared to Q1 2023. Operating expenses decreased by 29%, with a 12% increase in Non-IFRS Adjusted EBITDA loss. The Company plans a private placement of secured convertible debentures. Despite revenue effects from the Israel-Hamas war, IMC expects growth in the German market post-legalization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
-
Rhea-AI Summary

IM Cannabis Corp. will report its operational and financial results for the first quarter of 2024 on May 8th, 2024. The company, a key player in the medical cannabis sector operating in Israel and Germany, will hold a zoom conference at 9:00am ET to discuss the results with investors. A recording will be available on the company's website within 24 hours.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.07%
Tags
conferences earnings
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.02%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.9%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none

FAQ

What is the current stock price of Im Cannabis (IMCC)?

The current stock price of Im Cannabis (IMCC) is $0.1221 as of August 17, 2026.

What is the market cap of Im Cannabis (IMCC)?

The market cap of Im Cannabis (IMCC) is approximately 1.1M.